Respiratory Therapy
01 September 2026
Asthma Antiviral Nasal Spray Secures Funding for Clinical Trial
Vaccine
2 April 2026
Attitudes toward vaccines and antivirals for viral respiratory infections in a survey of US adults with chronic health conditionsPharmaTimes
29 January 2026
ENA Respiratory begins dosing in phase 2 study of INNA-051 nasal sprayBioCentury
5 January 2026
ENA Respiratory: Boosting prophylactic immunity with a pan-viral nasal sprayFinancial Review
27 October 2025
Bill Gates, Brandon Capital back Aussie flu-fighting start-upView article [Behind paywall]
PharmaTimes
22 October 2025
ENA Respiratory secures US$22.4m to advance nasal spray therapyThe Pharma Letter
18 December 2024
Airing in journal a further step forward for ENA RespiratoryBiotechDispatch
10 September 2024
ENA Respiratory secures extension of US funding for novel prophylactic antiviralBrandon Capital Website
7 May 2024
Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences PotentialForbes
12 September 2023
It beat the Covid virus, so why did this Aussie startup get $12m from the US military to start over?Respiratory Therapy
1 May 2022
Antiviral Nasal Spray Being Developed by ENA Respiratory, COPD FoundationFierce Pharma
28 February 2022
COPD Foundation links arms with ENA on antiviral nasal spray ahead of phase 2 trials in COVID-19, fluFierce Biotech
13 February 2022
ENA slices data to claim flu success in phase 2 and nasal spray’s wide-ranging potentialPharmafile
18 December 2020
ENA Respiratory’s nasal spray reduces COVID-19 replication by 96%BioWorld
29 September 2020
ENA Respiratory launches with AU$11.7M series A as it heads toward clinic with COVID-19 nasal sprayView article [behind a paywall]
The Standard
28 September 2020
Weekly nasal spray could offer protection from Covid-19, research finds
